#	Pagina
attuale pagina	/open-h2020/projects/207216/index.html

Opendata, web and dolomites

anTBiotic SIGNED

AnTBiotic – progressing TB drug candidates to clinical proof of concept

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

anTBiotic project word cloud

Explore the words cloud of the anTBiotic project. It provides you a very rough idea of what is the project "anTBiotic" about.

suitable dose humans gsk patients daily generating markers validity south salvage predict worldwide tuberculosis worrying explorative lactam week antbiotic proportion combination entities variety immediately infectious pipeline fuel optimal trials point never rivals resistant treatment intramuscular ct combine aids confronted regimen final drug cfu pioneering mdr of longer dosing oxaborole multidrug anti class candidate incorporate eba africa diseases intend least efficacy clinicians beta hiv extensively generate datasets benefit intravenous trial subjects adoption ascertain intervention eastern untreatable pet hopefully options clinical threatening strategies death once confidence first tb biomarkers ttp antibiotics proof precedent orally world

Project "anTBiotic" data sheet

The following table provides information about the project.

Coordinator	GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Organization address address: C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MADRID city: TRES CANTOS postcode: 28760 website: www.gsk.es/html/investigacion/espana.html contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.antbiotic.eu
Total cost	5˙819˙416 €
EC max contribution	5˙819˙416 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Organization address address: C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MADRID city: TRES CANTOS postcode: 28760 website: www.gsk.es/html/investigacion/espana.html contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (TRES CANTOS)	coordinator	1˙923˙768.00
2	TASK FOUNDATION NPC TASK FOUNDATION NPC Organization address address: M2 KARL BREMER HOSPITAL MIKE PIENAAR BOULEVARD BELLEVILLE city: CAPE TOWN postcode: 7530 website: www.task.org.za contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ZA (CAPE TOWN)	participant	1˙873˙804.00
3	FORSCHUNGSZENTRUM BORSTEL FORSCHUNGSZENTRUM BORSTEL Organization address address: Parkallee 1-40 city: BORSTEL postcode: 23845 website: www.fz-borstel.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BORSTEL)	participant	1˙242˙417.00
4	UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET Organization address address: HANSINE HANSENS VEG 14 city: TROMSO postcode: 9019 website: http://uit.no/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (TROMSO)	participant	644˙072.00
5	UNIVERSITY OF CAPE TOWN UNIVERSITY OF CAPE TOWN Organization address address: PRIVATE BAG X3 city: RONDEBOSCH postcode: 7701 website: www.uct.ac.za contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ZA (RONDEBOSCH)	participant	135˙353.00

Map

Project objective

Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to:

a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB

The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.

Deliverables

List of deliverables.
Project Website	Websites, patent fillings, videos etc.	2019-06-14 12:42:31
Dissemination Plan	Documents, reports	2019-06-14 12:42:31

Take a look to the deliverables list in detail: detailed list of anTBiotic deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Fabrizio Clarelli, Jingyi Liang, Antal Martinecz, Ines Heiland, Pia Abel zur Wiesch Multi-scale modeling of drug binding kinetics to predict drug efficacy published pages: , ISSN: 1420-682X, DOI: 10.1007/s00018-019-03376-y	Cellular and Molecular Life Sciences	2020-02-13
2020	Veronique R. de Jager, Naadira Vanker, Lize van der Merwe, Elana van Brakel, Morris Muliaditan, Andreas H Diacon Optimising Î²-lactams Against Tuberculosis published pages: , ISSN: 1073-449X, DOI: 10.1164/rccm.201911-2149le	American Journal of Respiratory and Critical Care Medicine	2020-02-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTBIOTIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTBIOTIC" are provided by the European Opendata Portal: CORDIS opendata.